Cargando…

The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients

BACKGROUND: High-dose methotrexate (HD-MTX) is widely used as a standard chemotherapeutic agent in pediatric cancers. Most research studies have confirmed the therapeutic efficacy of HD-MTX; however, strategies to prevent side effects vary among institutions, especially in developing countries, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Traivaree, Chanchai, Likasitthananon, Napakjira, Monsereenusorn, Chalinee, Rujkijyanont, Piya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188117/
https://www.ncbi.nlm.nih.gov/pubmed/30349379
http://dx.doi.org/10.2147/CMAR.S172117
_version_ 1783363160402558976
author Traivaree, Chanchai
Likasitthananon, Napakjira
Monsereenusorn, Chalinee
Rujkijyanont, Piya
author_facet Traivaree, Chanchai
Likasitthananon, Napakjira
Monsereenusorn, Chalinee
Rujkijyanont, Piya
author_sort Traivaree, Chanchai
collection PubMed
description BACKGROUND: High-dose methotrexate (HD-MTX) is widely used as a standard chemotherapeutic agent in pediatric cancers. Most research studies have confirmed the therapeutic efficacy of HD-MTX; however, strategies to prevent side effects vary among institutions, especially in developing countries, with limited monitoring of plasma methotrexate level. OBJECTIVE: To evaluate the effect of intravenous hydration during HD-MTX administration on plasma methotrexate clearance in pediatric oncology patients. MATERIALS AND METHODS: This study retrospectively reviewed 165 courses of HD-MTX administered to children with acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), or osteosarcoma. Demographic data of patients were collected. Adverse complications related to HD-MTX and 72-hour plasma methotrexate level were analyzed between patients receiving intravenous hydration ≥3,000 mL/m(2)/day and those receiving hydration <3,000 mL/m(2)/day. RESULTS: Among 56 HD-MTX (1.5 g/m(2)) courses in ALL, delayed methotrexate clearance was only found in one course administered with hydration <3,000 mL/m(2)/day. However, no correlation was observed between adverse complications and methotrexate levels. Of 34 HD-MTX (1.5–3 g/m(2)) courses in NHL, no significant correlation was observed between methotrexate levels and intravenous hydration. However, increased adverse complications were found in the course with delayed methotrexate clearance. Interestingly, among 75 HD-MTX (10–12 g/m(2)) courses in osteosarcoma, normal methotrexate clearance was successfully achieved in all courses administered with hydration ≥3,000 mL/m(2)/day compared with those administered with hydration <3,000 mL/m(2)/day (P=0.007). Furthermore, the courses administered with hydration <3,000 mL/m(2)/day and had delayed methotrexate clearance were more likely to develop adverse complications. CONCLUSION: Intravenous hydration of ≥3,000 mL/m(2)/day during HD-MTX administration is essentially required in osteosarcoma and can be considered as optional in ALL with HD-MTX <1.5 g/m(2), especially in developing countries with limited monitoring of plasma methotrexate level.
format Online
Article
Text
id pubmed-6188117
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61881172018-10-22 The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients Traivaree, Chanchai Likasitthananon, Napakjira Monsereenusorn, Chalinee Rujkijyanont, Piya Cancer Manag Res Original Research BACKGROUND: High-dose methotrexate (HD-MTX) is widely used as a standard chemotherapeutic agent in pediatric cancers. Most research studies have confirmed the therapeutic efficacy of HD-MTX; however, strategies to prevent side effects vary among institutions, especially in developing countries, with limited monitoring of plasma methotrexate level. OBJECTIVE: To evaluate the effect of intravenous hydration during HD-MTX administration on plasma methotrexate clearance in pediatric oncology patients. MATERIALS AND METHODS: This study retrospectively reviewed 165 courses of HD-MTX administered to children with acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), or osteosarcoma. Demographic data of patients were collected. Adverse complications related to HD-MTX and 72-hour plasma methotrexate level were analyzed between patients receiving intravenous hydration ≥3,000 mL/m(2)/day and those receiving hydration <3,000 mL/m(2)/day. RESULTS: Among 56 HD-MTX (1.5 g/m(2)) courses in ALL, delayed methotrexate clearance was only found in one course administered with hydration <3,000 mL/m(2)/day. However, no correlation was observed between adverse complications and methotrexate levels. Of 34 HD-MTX (1.5–3 g/m(2)) courses in NHL, no significant correlation was observed between methotrexate levels and intravenous hydration. However, increased adverse complications were found in the course with delayed methotrexate clearance. Interestingly, among 75 HD-MTX (10–12 g/m(2)) courses in osteosarcoma, normal methotrexate clearance was successfully achieved in all courses administered with hydration ≥3,000 mL/m(2)/day compared with those administered with hydration <3,000 mL/m(2)/day (P=0.007). Furthermore, the courses administered with hydration <3,000 mL/m(2)/day and had delayed methotrexate clearance were more likely to develop adverse complications. CONCLUSION: Intravenous hydration of ≥3,000 mL/m(2)/day during HD-MTX administration is essentially required in osteosarcoma and can be considered as optional in ALL with HD-MTX <1.5 g/m(2), especially in developing countries with limited monitoring of plasma methotrexate level. Dove Medical Press 2018-10-10 /pmc/articles/PMC6188117/ /pubmed/30349379 http://dx.doi.org/10.2147/CMAR.S172117 Text en © 2018 Traivaree et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Traivaree, Chanchai
Likasitthananon, Napakjira
Monsereenusorn, Chalinee
Rujkijyanont, Piya
The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients
title The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients
title_full The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients
title_fullStr The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients
title_full_unstemmed The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients
title_short The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients
title_sort effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188117/
https://www.ncbi.nlm.nih.gov/pubmed/30349379
http://dx.doi.org/10.2147/CMAR.S172117
work_keys_str_mv AT traivareechanchai theeffectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients
AT likasitthananonnapakjira theeffectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients
AT monsereenusornchalinee theeffectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients
AT rujkijyanontpiya theeffectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients
AT traivareechanchai effectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients
AT likasitthananonnapakjira effectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients
AT monsereenusornchalinee effectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients
AT rujkijyanontpiya effectofintravenoushydrationstrategyonplasmamethotrexateclearanceduringintravenoushighdosemethotrexateadministrationinpediatriconcologypatients